The SMA App at the Time of the Corona Pandemic: Support for Adult Patients and Doctors

The Corona pandemic demands protection from infection. These measures represent an essential change to the way people with spinal muscular atrophy (SMA) are cared for. In such scenarios, the

Successful Launch of the Observation Study on Nusinersen Applied in Adult SMA Patients

The study on Nusinersen is a nation-wide, systematic patient interview conducted with 100 patients with Spinal Muscular Atrophy (SMA) with the objective of gaining important new insights into

Study to Capture the Treatment with Nusinersen

Nusinersen (Spinraza®) is an approved drug for the treatment of 5q-associated Spinal Muscular Atrophy (SMA). Infants and children treated with Nusinersen may experience cessation of disease